Instructions for CME Participants

Sekeres M.A. . The myelodysplastic syndromes. Expert Opin Biol Ther. 2007; 7(3): 369–377.

National Comprehensive Cancer Network Practice Guidelines in Oncology v1.2009. http://nccn.org/professionals/physician_gls/. Accessed August 13, 2009.

Goldberg S.L. , Mody-Patel N. , Chen E.R. . Clinical and Economic Consequences of Myelodysplastic Syndromes in the United States: An Analysis of the Medicare Database. Blood (ASH Annual Meeting Abstracts). 2008; 112: 636.

Sekeres M.A. , Schoonen W.M. , Kantarjian H. . Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008; 100(21): 1542–1551.

Fenaux P. , Mufti G.J. , Hellstrom-Lindberg E. . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3): 223–232.